Tovorafenib

4 trials 1 recruiting Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

1 Completed trials

3 Sponsors

16 Countries

Phase III

Phase II

Phase I/II

Phase III: 1 Phase II: 2 Phase I/II: 1

Oversight events:

2 serious breaches 1 temporary halt across 2 trials

View oversight register →

Indications tested

Malignant glioma 2 Craniopharyngioma 1

Sponsors using this IMP

TargED Biopharmaceuticals B.V. 2 Prinses Maxima Centrum voor Kinderoncologie B.V. 1 Universitaetsklinikum Heidelberg AöR 1

All trials

4 total

PNOC029_Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults Pending

2024-511510-20-00 Phase II 3 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE) Pending

2024-516896-34-00 Phase I/II 5 countries Universitaetsklinikum Heidelberg AöR
A Phase 2 Study to Test Effects of Using DAY101 in Children with Brain Cancer Recruiting

2024-510691-20-00 Phase II 3 countries Day One Biopharmaceuticals Inc.
LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy Ended

2024-510742-13-00 Phase III 16 countries Day One Biopharmaceuticals Inc.

Showing 1–4 of 4 trials

← All drugs A–Z